CEO transition and cloud hurdles test the AI expansion
- Cellebrite’s core buyer is government, with Public Sector Customers accounting for more than 90% of 2025 revenue.
- The business is now mostly subscription-based, with total license subscription revenue at 90% of 2025 revenue.
- Management lowered 2026 guidance and appointed Shiv Ramji as CEO after cloud procurement delays elongated sales cycles.
- Genesis and Guardian Investigate move Cellebrite deeper into AI for investigations, generating early paid ARR.
- FedRAMP High approval helps U.S. federal cloud demand, which is accelerating back into mid-teens growth.
Cloud clearance meets execution risk
Cellebrite faces near-term execution hiccups despite a strong core engine. In August 2026, the board abruptly appointed Shiv Ramji as CEO and lowered full-year guidance. The problem involves foreign entity procurement hurdles. Sales cycles are taking longer because of U.S. Foreign Entity Permit rules and European Union freedom of information audits for cloud data storage.
The bull case centers on massive market expansion. The old U.S. federal slowdown is over, with the segment accelerating into mid-teens growth. The May 2026 FedRAMP High authorization lets key U.S. agencies use Cellebrite cloud products for sensitive work, which recently led to a large seven-figure Guardian win.
The new swing factor is AI. Genesis showed strong product-market fit after general availability, securing about $400,000 in annual recurring revenue in the final weeks of June 2026. Management believes the Investigative AI market could reach roughly $12.5 billion over four years, which could double the current business size.
The bear case asks if new leadership can fix the recent sales delays. The company must prove it can manage foreign entity procurement rules without losing deals or pushing timelines. Margins also face a near-term drag from a stronger Israeli shekel, and the Corellium acquisition still awaits U.S. national security approval.
Software sold to agencies
Cellebrite sells software to public sector agencies and some private companies. Public sector work is the center of the business. The 2025 filing says Public Sector Customers accounted for more than 90% of total revenue, and no single organization made up more than 5% of 2025 revenue.
Most sales are subscriptions. Customers pay for term licenses, SaaS products, support, and maintenance. Total license subscription revenue represented 90% of 2025 revenue, up from 88% in 2024. This makes revenue more repeatable than a pure hardware or services model. The launch of Genesis introduced a consumption-based token model, adding flexible usage revenue.
The model works best when an agency starts with digital forensics and then adds tools for evidence storage, analytics, case management, advanced lawful access, and AI. That is why Inseyets migration, Guardian adoption, and Genesis conversion are the key moving parts.
Where it can break is budget timing and permissions. Many buyers are government agencies, so spending can pause during program changes or audits. Recently, being a foreign entity has added procurement hurdles for cloud adoption in the U.S. and Europe.
From phones to full cases
Inseyets
Inseyets is the core digital forensics suite used to collect and review evidence from phones, computers, cloud apps, and vehicles. Management said nearly 65% of the installed digital forensics base had converted to Inseyets by the end of Q2 2026.
Advanced lawful access
These tools help authorized users access locked devices under legal authority. They are valuable, but they also sit closest to regulatory and device-maker friction.
Guardian Forensics and Guardian Collaborate
Guardian products help store, share, review, and manage digital evidence. They push Cellebrite from device extraction into the larger workflow around a case.
Guardian Investigate
Guardian Investigate is an AI-powered system of record for case management. It is now in general availability and forms a major piece of the AI growth strategy.
Genesis
Genesis is Cellebrite’s agentic AI product for faster data insight. It operates on a consumption-based token model and secured roughly $400,000 in ARR shortly after launch.
Corellium
Corellium adds Arm-based virtualization software for mobile security research and vulnerability work. Cellebrite closed the deal in December 2025, but CFIUS approval remains pending.
SCG Canada drone forensics
SCG Canada gives Cellebrite tools to extract, decode, and view evidence from common drones. The acquisition adds an immediate entry into a growing market.
Subscription carries the mix
The structured mix uses fiscal 2025 revenue lines from the 2025 Form 20-F because the available filing section discloses revenue by type. Geography is still important: the Americas is the largest region, with U.S. federal growth currently accelerating into the mid-teens.
What could still go wrong
Foreign entity status slows deals
High impact · High oddsCellebrite is a foreign entity, which triggers extra review for cloud software contracts. In Q2 2026, the company cited U.S. Foreign Entity Permit rules and European Union freedom of information audits as reasons for elongated sales cycles. If these delays persist, growth could stall.
Genesis does not scale
High impact · Medium oddsGenesis has early usage and some paid revenue, but the hard part is mass adoption. Management’s AI target is large enough that even a modest miss could reset investor expectations. If trial users do not become paid seats, the AI story stalls.
Corellium review adds limits
Medium impact · Medium oddsCellebrite closed the Corellium deal in December 2025, but CFIUS approval remains pending. CFIUS is the U.S. review process for foreign investment in sensitive businesses. Restrictions could limit how Cellebrite integrates or sells Corellium into certain defense and intelligence accounts.
Device access gets harder
High impact · Medium oddsCellebrite’s value depends on keeping pace with new phone hardware, operating systems, encryption, and app changes. Regulators and device makers can also push back on tools that access locked or protected data.
Shekel strength pinches margins
Medium impact · Medium oddsCellebrite reports in dollars, but a meaningful part of its costs are in Israeli shekels. A stronger shekel raises dollar-reported expenses and can compress adjusted EBITDA margins. Management calls this a near-term headwind.
In one breath
What does Cellebrite actually do?
Cellebrite sells software that helps authorized users collect, decode, manage, and analyze digital evidence. Its main customers are law enforcement, defense, intelligence, and other public sector agencies.
Why does FedRAMP matter for Cellebrite?
FedRAMP is a U.S. government cloud security approval. Cellebrite received FedRAMP High authorization in May 2026, which makes it easier for federal agencies to buy and use its cloud products for sensitive data.
Is Cellebrite an AI company now?
AI is becoming a bigger part of the story through products like Genesis and Guardian Investigate. The core business is still digital forensics, but management believes AI could eventually double the total addressable market.
What is the biggest risk for CLBT stock?
The biggest risk is execution. The company recently changed CEOs and lowered guidance because of long sales cycles tied to foreign entity cloud procurement rules. The stock relies heavily on smooth government spending.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Software - Infrastructure companies
Companies near Cellebrite DI Ltd. in Finn's Software - Infrastructure industry ranking.
